Navigation Links
China BCT Reschedules Conference Call to Discuss Third Quarter 2010 Results
Date:11/9/2010

China BCT Reschedules Conference Call to Discuss Third Quarter 2010... -- LIUZHOU CITY, Guangxi, China, Nov. 9, 2010 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Retail, OTC, SmallCap, Health Care & Hospitals, Pharmaceuticals Click to view news release full screen  

China BCT Reschedules Conference Call to Discuss Third Quarter 2010 Results

 

LIUZHOU CITY, Guangxi, China, Nov. 9, 2010 /PRNewswire-Asia-FirstCall/ -- China BCT Pharmacy Group, Inc., (OTC Bulletin Board: CNBI), ("China BCT" or the "Company"), a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced that it has rescheduled the timing of the conference call to discuss its third quarter 2010 results.

The Company will now host a conference call at 10:00 a.m. Eastern Standard Time on Wednesday, November 10, 2010. The call was previously scheduled for Tuesday, November 9, 2010 at 9:00 AM Eastern Standard Time.

Mr. Hui Tian Tang, Chairman and Chief Executive Officer of the Company, and Ms. Shelly Zhang, Chief Financial Officer of the Company, will host the conference call. The Company will release its financial results for the third quarter 2010 prior to the call.

To participate in the live teleconference, please dial 866-355-4234 five to ten minutes before the scheduled start time. International callers are invited to call 706-643-7041.  Please refer to conference ID 23590384.  

If you are unable to participate in the call at this time, a replay will be available for 14 days starting on November 10, 2010 at 11:00 a.m. Eastern Standard Time. To access the replay, dial 800-642-1687. International callers please dial 706-645-9291, and enter conference ID 23590384.

About China BCT China BCT is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals products through its subsidiaries, Guangxi Liuzhou Baicaotang Medicine Limited, Hefeng Pharmaceutical Co. Limited, and Guangxi Liuzhou Baicaotang Medicine Retail Limited, each located in Guangxi province, China. The Company operates a large regional retail network in Guangxi province, consisting of 170 directly owned retail stores in Guangxi province and currently over 8,000 products are distributed through the Company's wholesale distribution network. For more information, please visit www.china-bct.com

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements related to anticipated revenue and payback period of the new stores. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this presentation.Company Contact:

Investor Relations Contact:Ms. Shelly Zhang, Chief Financial Officer

Mr. Crocker Coulson, President China BCT Pharmacy Group, Inc.

CCG Investor RelationsEmail: shelly.zhang@china-bct.com

Email: crocker.coulson@ccgir.com Tel: (86) 772-363-8318

Tel: +1-646-213-1915Website: www.china-bct.com
'/>"/>

SOURCE China BCT Pharmacy Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the worldwide ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin America ... are provided for the period 2015 through 2022. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/24/2017)... , Feb. 23, 2017  This report analyzes ... by the following Products: Intermediates, Analytical, ... the report include Pharmaceuticals, and Agrochemicals. The report provides ... , Europe , and Rest ... the period 2015 through 2022. Also, a six-year historic ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... tooth replacement options at his office, Antoine Dental Center. Currently, patients can get ... Some restrictions may apply, but patients can learn more about these offers by ...
(Date:2/24/2017)... ... , ... An in-depth computational analysis of genetic variants implicated in both schizophrenia ... that may explain why susceptibility to one of the disorders could place individuals at ... in the journal npj Schizophrenia. , “There is a wealth of genomic data ...
(Date:2/24/2017)... NY (PRWEB) , ... February 24, 2017 , ... In ... needs to be a top priority because it’s not if you will be attacked, ... safety, especially when it comes to digital health care. , Improvements in auditing and ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An Australian ... account of his paramedic experiences. Schanssema describes the tragedies he saw, as well as ... overcome them. , Schanssema, initially unsure of the career path he wanted to take, ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
Breaking Medicine News(10 mins):